Solid phase immobilization of phospholipids and cofactor proteins via covalent attachment
AssigneeBio-Rad Laboratories, Inc.
InventorsMichael Watkins, Tony Prestigiacomo, Steven Binder, Woei Tan
Life of this patent
Estimating the term…
Abstract
The present invention provides methods and reagents for detecting anti-phospholipid-cofactor protein-antibodies.
Claims18
An anti-phospholipid-cofactor protein-antibody detection reagent, the anti-phospholipid-cofactor protein detection reagent comprising a phospholipid moiety, a cofactor protein, and a carrier,
- wherein the phospholipid moiety is covalently bound to the cofactor protein and the cofactor protein is bound to the carrier.
A method of determining a likelihood of developing an anti-phospholipid syndrome (APS) in a patient, the method comprising the steps of:
- a) determining a level of an antibody that binds to an antigen for APS, the antigen selected from the group consisting of a cardiolipin moiety, a beta-2-glycoprotein I (β2GPI) protein, and a cardiolipin-β2GPI protein complex, wherein the a cardiolipin-β2GPI protein complex comprises a cardiolipin moiety covalently bound to the β2GPI protein;
- and
- b) comparing the level of antibodies determined in step a) with levels of said antibodies from a normal control, wherein (i) levels of the antibody from the patient that are less than or substantially equal to levels of the antibody from the normal control indicate low or no likelihood of developing APS;
- and (ii) levels of the antibody from the patient that are higher than levels of the antibody from the normal control indicate an increased likelihood of developing APS.
A method of determining a likelihood of developing an anti-phospholipid syndrome (APS) in a patient, the method comprising the steps of:
- a) determining a level of an antibody that binds to an antigen for APS, the antigen selected from the group consisting of a cardiolipin moiety;
- a beta-2-glycoprotein I (β2GPI) protein;
- a cardiolipin-β2GPI protein complex, wherein the a cardiolipin-β2GPI protein complex comprises a cardiolipin moiety covalently bound to the β2GPI protein;
- a phosphatidylserine moiety, a phosphatidylserine-β2GPI protein complex;
- and a prothrombin protein;
- and
- b) comparing the level of antibodies determined in step a) with levels of said antibodies form a normal control, wherein (i) levels of the antibody from the patient that are less than or substantially equal to levels of the antibody from the normal control indicate low or no likelihood of developing APS;
- and (ii) levels of the antibody from the patient that are higher than levels of the antibody from the normal control indicate an increased likelihood of developing APS.
An anti-cardiolipin-cofactor protein-antibody detection reagent, the anti-cardiolipin-cofactor protein detection reagent comprising a cardiolipin moiety, a beta-2-glycoprotein I (μ2GPI) protein, and a carrier,
- wherein the cardiolipin moiety is covalently bound to the β2GPI protein and the β2GPI protein is bound to the carrier.
Dependencies are inferred from the claim text.